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S U M M A R Y
Objective: Hepatitis E virus (HEV) infection is responsible for over 50% of acute viral hepatitis cases, and
the blood transfusion route has emerged as a possible means of sporadic HEV infection. The aim of this
study was to determine the seroprevalence of HEV among blood donors in East China.
Methods: Blood samples were collected consecutively between January and June 2011 from 486 blood
donors living in Jiangsu Province, East China. Anti-HEV IgG was tested by ELISA.
Results: One hundred and thirteen blood donors developed HEV IgG antibody, indicating the prevalence
of HEV IgG seropositivity to be 23.3%. HEV IgG seropositivity was 25.3% (90/356) in the male group,
signiﬁcantly higher than that in the female group (17.7%, 23/130) (p < 0.05). The donors who had
donated more than 10 times had signiﬁcantly higher HEV IgG seropositivity than the other groups
(p < 0.05). Furthermore, donors aged 50–55 years had signiﬁcantly higher HEV IgG seropositivity than
the other age groups (p < 0.05).
Conclusions: We investigated HEV seroprevalence among blood donors in East China. Our data will help
identify the risk factors for HEV infection and provide guidance on controlling the safety of blood
transfusions in the clinical setting.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Hepatitis E virus (HEV) infection is responsible for over 50% of
acute viral hepatitis cases and has become an important public
health concern worldwide. Hepatitis E is most common in
developing countries with inadequate water supplies and envi-
ronmental sanitation, and large hepatitis E epidemics have been
reported in Asia, the Middle East, Northern and Central Africa, and
Central America. However, sporadic HEV infection has been
reported in developed countries, including the USA and European
countries.1–4 Recently, the blood transfusion route has emerged as
a possible means of sporadic HEV infection in several countries.5–7
HEV immunoglobulin G (IgG) prevalence ranges between 3%
and 20%, and the reliability of HEV IgG seropositivity enzyme-
linked immunosorbent assay (ELISA) kits has been proved.8 China* Corresponding author. Tel.: +86 13758207477; fax: +86 05174921711.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).is a large country with a large population of blood donors. While
several studies have reported the prevalence of HEV infection in
different groups in China,9 the prevalence of HEV infection in blood
donors in China remains unclear. Therefore, the aims of this study
were to investigate whether HEV could be transmitted by the blood
transfusion route and to analyze the seroprevalence of HEV strains
among blood donors in Jiangsu Province in East China.
2. Methods
2.1. Population and sample collection
This study was approved by the Ethics Committee of Nanjing
Medical University and all participants gave informed consent. A
questionnaire was completed for each participant to collect
information on age, sex, and history of blood donation. Blood
samples were collected consecutively between January and June
2011 from 486 blood donors living in the regions of Huai’an and
Lianyungang, Jiangsu Province, East China, comprising both urbanciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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HBsAg seropositivity 8 (9.76%) 37 (9.16%) 0.845
HCV antibody
seropositivity
5 (6.10%) 23 (5.69%) 0.893
HEV, hepatitis E virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HBsAg,
hepatitis B surface antigen.
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general population, blood collections at university campuses or
army centers were excluded.
2.2. Detection of antibodies against HEV
Serum samples were tested by ELISA for IgG, as described
previously.10 HEV antibodies were detected by adding 100 ml of
horseradish peroxidase-labeled monoclonal anti-human IgG
(Pierce, USA) appropriately diluted in phosphate buffered saline-
Tween with 1% non-fat milk followed by incubation for 30 min at
37 8C. The antibody complexes were detected by the addition of
100 ml orthophenylenediamine (Abbott, USA) for 10 min for HPRO-
labeled antibodies. The cut-off was statistically established as the
mean of the optical density (OD) value at 492 nm. All participants
had been tested for hepatitis B surface antigen (HBsAg) and
antibodies to hepatitis C virus (anti-HCV) by ELISA before blood
donation, and the information was collected from the blood
transfusion center.
2.3. Statistical analysis
Data were expressed as the mean  standard deviation and were
analyzed using SPSS version 12 software (SPSS Inc., Chicago, IL, USA).
A p-value of <0.05 was accepted as statistically signiﬁcant.
3. Results
In this study we enrolled 486 blood donors, including 356
(73.3%) males and 130 (26.7%) females. Their age ranged from 22 to
55 years (mean 43  6 years). The ELISA assay showed that 113 blood
donors developed HEV IgG antibody, indicating the prevalence of HEV
IgG seropositivity to be 23.3%.
Next we analyzed the prevalence of HEV IgG seropositivity in
the 486 blood donors. In the male group, HEV IgG seropositivity
was 25.3% (90/356), signiﬁcantly higher than that in the female
group (17.7%, 23/130) (Table 1, p < 0.05). Of note, the percentage of
HEV IgG seropositivity increased with the number of times blood
was donated. Those donors who had donated more than 10 times
had signiﬁcantly higher HEV IgG seropositivity than the other
groups (Table 1, p < 0.05). Furthermore, the percentage of HEV IgG
seropositivity increased with the age of the blood donors. Those
donors aged between 50 and 55 years had signiﬁcantly higher HEV
IgG seropositivity than the other age groups (Table 1, p < 0.05).
Furthermore, we analyzed the correlation between HEV
infection and hepatitis B virus (HBV) or hepatitis C virus (HCV)
co-infection in blood donors. The results showed that the
percentages of HBsAg seropositivity and HCV antibody seroposi-
tivity were slightly higher in donors with HEV IgG seropositivity
than in those with HEV IgG seronegativity, but there were no
signiﬁcant differences (Table 2, p < 0.05).Table 1
Prevalence of HEV IgG seropositivity in blood donors (n = 486)
Characteristic HEV positive IgG p-Value
Sex Male 90/356 (25.3%) 0.011
Female 23/130 (17.7%)
Number of times a
donation had been made
<5 44/245 (18.0%)
5–10 40/156 (25.6%) 0.213
10 29/85 (34.1%) 0.005
Age, years <40 5/42 (11.9%)
40–50 47/246 (19.1%) 0.285
50–55 61/198 (30.8%) 0.017
HEV, hepatitis E virus.4. Discussion
Transfusion-transmitted infections are a major problem asso-
ciated with blood transfusion. While many studies have investi-
gated the prevalence of HIV, HBV, and HCV infection in blood
donors, only recently has the prevalence of HEV infection in blood
donors been examined.5–8 In this study, we screened 486 blood
samples from blood donors in East China and found the HEV
seroprevalence to be 16.9%; this rate is signiﬁcantly higher than
the 4.9% recently reported in blood donors in southwest
Switzerland,7 but is close to the rate reported by Ijaz, who
conducted a retrospective screening study comparing seropreva-
lence rates in blood samples taken in 1991 and 2004 and found
similar rates among the two groups (13.0% in 1991 and 13.5% in
2004).11 Our rate is signiﬁcantly lower than the rate of 22.7%
reported in illegal blood donors in central China.12 This is
reasonable because illegal blood donors have a greatly increased
risk of HEV infection.
Age has been shown to be a risk factor for HEV infection, and
older age is correlated with HEV antibody seropositivity.13
Consistent with previous studies, we found that the percentage
of HEV IgG seropositivity increased with the age of the blood
donors in the current study. For those donors aged between 50 and
55 years in particular, HEV IgG seropositivity was signiﬁcantly
higher.
Sex may be another risk factor for HEV infection because we
found that 25.3% of male blood donors were HEV seropositive
compared to 17.7% of female donors. These data are consistent
with those of a previous study showing higher prevalence of anti-
HEV reactivity in male than in female blood donors in Iran.6 Thus it
appears that male blood donors are more likely to become infected
by HEV than female donors.
Blood donors are generally healthy, without any recent history
of hepatitis or other illness.14 In this study we found that the
percentage of HEV IgG seropositivity increased with the number of
times blood was donated. In particular, the donors who had
donated more than 10 times had signiﬁcantly higher HEV IgG
seropositivity than those who had donated fewer times. Although
we found no signiﬁcant correlation between HEV seropositivity
and blood-borne hepatitis viruses such as HBV and HCV, these data
suggest that frequent blood donation may increase the risk of HEV
infection, because HEV can be transmitted via similar or over-
lapping routes as HCV.15
Due to the limitations of available resources, we only detected
blood donors in two regions of Jiangsu Province, East China in this
study. Further efforts are needed to increase the sample size and
regions involved.
In conclusion, this is the ﬁrst study to investigate HEV
seroprevalence among blood donors in East China. Our results
demonstrate that HEV infection is prevalent in this population.
Males, individuals aged more than 50 years old, and individuals
who have donated blood more than 10 times are more likely to be
HEV-seropositive. These data will help identify the risk factors for
W. Zhuang et al. / International Journal of Infectious Diseases 26 (2014) 9–11 11HEV infection and provide guidance on controlling the safety of
blood transfusions in the clinical setting.
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